Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8687300 | 0.93 | CYP1A2 (0.44) | LMNACYP2A6KCNH2GRM5MAOA | |
| SCHEMBL20015814 | 0.82 | LMNA (0.57) | LMNACYP2A6KCNH2GRM5MAOA | |
| SCHEMBL719360 | 0.82 | LMNA (0.57) | LMNACYP2A6KCNH2GRM5MAOA | |
| Charcoal, Activated SCHEMBL31286310 | 0.79 | KCNH2 (0.54) | LMNACYP2A6KCNH2GRM5MAOA | |
| SCHEMBL6045133 | 0.76 | GRM5 (0.47) | LMNACYP2A6KCNH2GRM5MAOA | |
| SCHEMBL2879214 | 0.74 | LMNA (0.47) | LMNACYP2A6KCNH2GRM5MAOA | |
| SCHEMBL23602026 | 0.72 | LMNA (0.44) | LMNACYP2A6KCNH2GRM5MAOA | |
| SCHEMBL5252697 | 0.72 | GRM5 (0.39) | GRM5MAOAMAOBIDO1APP | |
| SCHEMBL18245117 | 0.72 | LMNA (0.44) | LMNACYP2A6KCNH2GRM5MAOA | |
| SCHEMBL990765 | 0.72 | LMNA (0.44) | LMNACYP2A6KCNH2GRM5MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2052251-A1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-29 | — | — | EP | claimed |
| WO-2008013556-A1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-01-31 | — | — | WO | claimed |
| US-6673804-B1 | PREVENTING OR TREATING ARTHRITIS (PARTICULARLY OSTEOARTHRITIS) OR INHIBITING METASTASIS, INVASION OR GROWTH OF CANCER (PARTICULARLY BREAST CANCER) | SANKYO COMPANY, LIMITED (JP) | 2004-01-06 | — | — | US | claimed |
| EP-0998454-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2003-03-26 | — | — | EP | claimed |
| US-6271262-B1 | AMIDESULFONAMIDE COMPOUNDS AS ENZYME INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-08-07 | — | — | US | claimed |
| CN-1304402-A | Sulfonamide derivatives | SANKYO CO (JP) | 2001-07-18 | — | — | CN | claimed |
| EP-1069110-A1 | SULFONAMIDE DERIVATIVES | Sankyo Company Limited (JP) | 2001-01-17 | — | — | EP | claimed |
| EP-0998454-A2 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-05-10 | — | — | EP | claimed |
| WO-1999003826-A2 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-01-28 | — | — | WO | claimed |
| CN-114262290-B | 4-methylene pyrrolidine-2-thioketone compound, and synthetic method and application thereof | 华东师范大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-114262290-A | 4-methylene pyrrolidine-2-thioketone compound and synthesis method and application thereof | 华东师范大学 | 2022-04-01 | — | — | CN | disclosed |
| WO-2018157800-A1 | MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-09-07 | — | — | WO | disclosed |
| US-20180244699-A1 | 1-HYDROXY-3H-2,1-BENZOXABOROLE DERIVATIVES AND THEIR USE AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-08-30 | — | — | US | disclosed |
| EP-3337809-A1 | 1-HYDROXY-3H-2,1-BENZOXABOROLE DERIVATIVES AND THEIR USE AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-06-27 | — | — | EP | disclosed |
| US-5552409-A | PHYTOPATHOGENIC, RICE | ROHM AND HAAS COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| US-5245034-A | Compound having vessel smooth muscle relaxation activity | Hidaka, Kiroyoshi (JP) | 1993-09-14 | — | — | US | disclosed |
| US-5216150-A | Muscle relaxant; enzyme inhibitor and platelet aggutination inhibitor | Hidaka, Hiroyoshi (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0478195-A1 | Dihydropyridazinones, pyridazinones and related compounds as fungicides | ROHM AND HAAS COMPANY (US) | 1992-04-01 | — | — | EP | disclosed |
| US-5081246-A | Isoquinolino sulfonamino derivatives | Hidaka, Hiroyoshi (JP) | 1992-01-14 | — | — | US | disclosed |
| US-4559082-A | THIOCARBAMATES WITH UNSATURATED ARYL SULFIDES, SULFOXIDES OR SULFONES | STAUFFER CHEMICAL CO. (US) | 1985-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244699-A1 | 1-HYDROXY-3H-2,1-BENZOXABOROLE DERIVATIVES AND THEIR USE AS MICROBIOCIDES | CBR3, HCRTR2, HCAR3 | LMNA 4316/4885CYP2A6 534/4885KCNH2 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.